17:02 EDT Sellas Life Sciences (SLS) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- Sellas Life Sciences price target raised to $10 from $7.50 at Alliance Global
- Sellas Life Sciences options imply 6.2% move in share price post-earnings
- Sellas Life Sciences to present preclinical SLS009 data at AACR conference
- SELLAS (SLS): Advancing AML Pipeline, Strengthened Balance Sheet, and Upcoming Catalysts Drive Higher Target and Buy Rating
- Sellas announces enrollment of first patient in Phase 2 SLS009 trial